Continuous Glucose Monitors Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Continuous Glucose Monitors Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Continuous Glucose Monitors Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Continuous Glucose Monitors pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Continuous glucose monitoring system is used for the continuous measurement of blood glucose. The Continuous glucose monitoring system includes an implantable sensor with wireless transmission capability and a monitor.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Continuous Glucose Monitors under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Continuous Glucose Monitors and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Continuous Glucose Monitors under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
Introduction
Continuous Glucose Monitors Overview
Products under Development
Continuous Glucose Monitors - Pipeline Products by Stage of Development
Table Continuous Glucose Monitors - Pipeline Products by Stage of Development
Table Continuous Glucose Monitors - Pipeline Products by Stage of Development
Continuous Glucose Monitors - Pipeline Products by Territory
Table Continuous Glucose Monitors - Pipeline Products by Territory
Table Continuous Glucose Monitors - Pipeline Products by Territory
Continuous Glucose Monitors - Pipeline Products by Regulatory Path
Table Continuous Glucose Monitors - Pipeline Products by Regulatory Path
Table Continuous Glucose Monitors - Pipeline Products by Regulatory Path
Continuous Glucose Monitors - Pipeline Products by Estimated Approval Date
Table Continuous Glucose Monitors - Pipeline Products by Estimated Approval Date
Table Continuous Glucose Monitors - Pipeline Products by Estimated Approval Date
Table Eclipse 3 ICGM System - Feasibility Trial to Evaluate the Eclipse 3 Continuous Glucose Monitoring System for Individuals with Type 1 Diabetes Mellitus - Australia (FREE - AU Trial)
Aug 08, 2024: Quebec Expands Public Reimbursement of Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System to More Adults with Diabetes
Aug 07, 2024: Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices
Jul 31, 2024: Abbott Issues Voluntary Medical Device Correction for a Small Number of FreeStyle Libre 3 Sensors in the U.S.
Jul 24, 2024: Abbott Issues Voluntary Medical Device Correction for a Small Number of Freestyle Libre 3 Sensors in the U.S
Jul 08, 2024: Henry Schein to Webcast Second Quarter 2024 Conference Call on Tuesday, August 6, 2024 at 10:00 a.m. ET
Jun 27, 2024: Abbott Hosts Conference Call for Second-Quarter Earnings
Jun 24, 2024: Trinity Biotech to Begin European Pre-pivotal Trial to Optimize Its CGM Sensor
Jun 20, 2024: Dexcom Expands AID Partnership Into The Netherlands
Jun 19, 2024: Abbott Diabetes Receives 510(K) Clearance For Libre Rio Continuous Glucose Monitoring System
Jun 19, 2024: Hagar Announces Published Clinical Data on GWave Technology
Jun 17, 2024: GlucoModicum ups manufacturing after positive data for needle-free CGM
Jun 13, 2024: Abbott Medical Receives 510(K) Clearance For Lingo Glucose
Jun 13, 2024: Medtronic Confirms Global Layoffs
Jun 11, 2024: FDA approves Abbott's Lingo and Libre Rio glucose monitoring systems
Jun 03, 2024: Nova Scotia Now Providing Coverage for Dexcom Continuous Glucose Monitoring Systems
May 21, 2024: Henry Schein to Present at Investor Conferences in June 2024
May 17, 2024: Senseonics Receives DeNovo Clearance for Eversense AP CGM System
May 13, 2024: Senseonics and Mercy Collaborate to Improve Diabetes Population Health Management
May 06, 2024: Abbott Diabetes Care Receives An Additional 510(k) Clearance For FreeStyle Libre 2 Flash Glucose Monitoring System
May 06, 2024: Abbott Diabetes Care Receives An Additional 510(k) Clearance For FreeStyle Libre 3 Continuous Glucose Monitoring System
Apr 30, 2024: Glutality powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology
Apr 19, 2024: Lee's Pharmaceutical Notice of Annual General Meeting
Apr 08, 2024: Draper Drives Growth Strategy with Appointment of Carrie George as Chief Financial Officer
Apr 03, 2024: Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
Mar 26, 2024: Going Beyond Blood Glucose Monitoring: How CGM's Panoramic Perspective Redefines Diabetes Management
Mar 12, 2024: Medtronic To Present At Barclays Global Healthcare Conference
Mar 06, 2024: Know Labs' Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study
Mar 06, 2024: Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029
Mar 04, 2024: Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
Feb 23, 2024: Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
Feb 13, 2024: Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
Feb 09, 2024: Invitation to Senzime's Fourth Quarter 2023 Report Presentation
Feb 06, 2024: Dexcom launches real-time CGM solution Dexcom ONE+ in Europe
Jan 17, 2024: Huons Donates 6,000 Continuous Glucose Monitors To Type 1 Diabetes Patients
Jan 11, 2024: Veri Releases New Metabolic Health Program
Jan 03, 2024: Henry Schein to Present at J.P. Morgan's Healthcare Investor Conference
Nov 12, 2023: Mubadala Health Kicks Off Two-Day Diabetes Conference in Abu Dhabi
Nov 07, 2023: Henry Schein to Present at Upcoming Investor Conferences in November 2023
Oct 23, 2023: Invitation to Senzime's Third Quarter 2023 Report Presentation
Oct 18, 2023: Edwards Lifesciences to Host Earnings Conference Call on October 25, 2023
Oct 10, 2023: Tandem Diabetes Care to Announce Third Quarter 2023 Financial Results on November 1, 2023
Sep 19, 2023: Abbott and Weightwatchers Connected App Experience Is Now Available for People Living With Diabetes
Sep 19, 2023: Lifecare - Sanofi Product Development Agreement Update
Sep 11, 2023: Nemaura Medical Completes 100 Patient Study for Sugarbeat 24-Hour Wear and Reports Interim Results
Sep 05, 2023: Henry Schein to Present at Investor Conferences in September 2023
Aug 28, 2023: Edwards Lifesciences to Present at the 2023 Wells Fargo Healthcare Conference